Pinot Bio develops next-generation antibody-drug conjugates (ADCs) and targeted therapies, including the PINOT-ADC™ platform and the DNMT1 inhibitor NTX-301, to enhance the efficacy and safety of cancer treatments. The company addresses the limitations of existing cancer therapies by providing more effective and less toxic options for patients with solid tumors and hematological malignancies.
Funding
$39.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LGFounders
Product
Problem
Existing cancer therapies often lack efficacy and have significant toxicity issues, especially for patients with solid tumors and hematological malignancies. Traditional antibody-drug conjugates (ADCs) can have limitations in terms of drug delivery and safety profiles.
Solution
Pinot Bio is developing next-generation ADCs and targeted therapies designed to improve both the efficacy and safety of cancer treatments. Their PINOT-ADC™ platform aims to overcome the limitations of current ADC technology through novel linker technology and payload mechanisms. They are also developing NTX-301, a DNMT1 inhibitor, as a targeted therapy. The company's approach focuses on providing more effective and less toxic treatment options for a range of cancers.
Target Audience
The primary target audience includes patients with solid tumors and hematological malignancies, as well as pharmaceutical companies seeking to license or co-develop novel cancer therapies.
Features
- PINOT-ADC™ platform designed to overcome limitations of existing ADC drugs.
- NTX-301, a best-in-class nucleoside-based DNMT1 inhibitor.
- Development of dual payload ADCs to improve efficacy compared to single payload ADCs.
- Linker technology designed for high hydrophilicity and sequential cleavage to maximize safety.
- PBX-7, a TOP1 inhibitor, demonstrating tumor suppression and bystander effects comparable to Enhertu in preclinical studies.